



## LIST OF FIGURES

No.	Title	Page
<b>Prologue</b>		
<b>1.1</b>	Hallmarks of Cancer	<b>2</b>
<b>1.2.1</b>	Radical Cause of Cancer: Tobacco in different for forms	<b>3</b>
<b>1.2.2</b>	Molecular-Pathogenesis of Cancer	<b>5</b>
<b>Introduction</b>		
<b>2.2</b>	Major risk factors attributing to cause of cancer.	<b>10</b>
<b>2.3.1</b>	Incidence, mortality and prevalence of cancer worldwide by continent.	<b>11</b>
<b>2.3.2</b>	New cancer cases (incidence) and prevalent cases (five year survival) in thousands by cancer site in 2002.	<b>12</b>
<b>2.3.3</b>	Head and neck sites in human body	<b>13</b>
<b>2.5.1</b>	Top major cancers by site irrespective of gender registered at G.C.R.I., 2003.	<b>15</b>
<b>2.5.2</b>	Incidence of Tobacco related cancers at G.C.R.I., 2003.	<b>15</b>
<b>2.6.1</b>	Implications of ROS and RNS mediated damage in pathogenesis of oral cancer	<b>22</b>
<b>2.8.1</b>	Pictorial illustration of different stages of cancer.	<b>26</b>
<b>2.12.1</b>	Pathogenesis of oral premalignant lesions.	<b>29</b>
<b>2.13.1</b>	Molecular Progression of Oral Cancer	<b>33</b>
<b>Materials and Methods</b>		
<b>3.1</b>	Principle of ECL western blot method	<b>72</b>
<b>3.2</b>	Diagrammatic representation of western blot procedure	<b>75</b>
<b>3.3</b>	Flow chart depicting the procedure of gelatin zymography	<b>78</b>
<b>3.4</b>	Pictorial representation of principle of Sandwich ELISA method	<b>80</b>
<b>3.5</b>	Assay for anti -p53 antibodies by Sandwich ELISA	<b>82</b>
<b>3.6</b>	Schematic layout of Sandwich ELISA for active NFκB-p65	<b>84</b>
<b>3.7</b>	Schematic layout for the assay procedure of Quantikine assay of Sandwich ELISA	<b>87</b>
<b>3.8</b>	Pictorial representation for serial dilutions of MMP-2, MMP-9, TIMP-1 and TMP-2 standards	<b>88</b>
<b>Results- 4.1</b>		
<b>4.1.1</b>	Standard curve for NFκBp65	<b>91</b>
<b>4.1.2</b>	Representative pattern for NFκBp65 expression in tissues	<b>91</b>
<b>4.1.3</b>	Expression of NFκBp65 protein levels in tissues	<b>92</b>
<b>4.1.4</b>	ROC curve for NFκBp65 in oral cancer patients	<b>93</b>
<b>4.1.5</b>	Representative pattern for iNOS expression in tissues	<b>97</b>
<b>4.1.6</b>	iNOS expression in malignant and adjacent normal oral tissues	<b>97</b>
<b>4.1.7</b>	ROC curve for iNOS expression in oral cancer patients	<b>98</b>
<b>4.1.8</b>	Representative pattern for Hsp-70 expression in OSCC	<b>100</b>

	tissues	
<b>4.1.9</b>	Hsp-70 expression in oral SCC tissues	<b>101</b>
<b>4.1.10</b>	ROC curve for Hsp-70 expression in oral cancer patients	<b>102</b>
<b>4.1.11</b>	Representative pattern for Bcl-2 expression in tissues	<b>104</b>
<b>4.1.12</b>	Representative pattern for Bax expression in tissues	<b>104</b>
<b>4.1.13</b>	Expression of apoptotic proteins in malignant and adjacent normal oral tissues	<b>105</b>
<b>4.1.14</b>	ROC curve for Bcl-2 in oral cancer patients	<b>106</b>
<b>4.1.15</b>	Representative gelatin zymogram and standard curves for Gelatinase-A [MMP-2]: (A; Zymogram, B; latent, C; active) standards	<b>109</b>
<b>4.1.16</b>	Representative pattern for gelatinase-A (MMP-2) in oral SCC tissues	<b>110</b>
<b>4.1.17</b>	Comparison of Latent, active, total and activation ratio of Gelatinase-A (MMP-2) in oral SCC tissues	<b>111</b>
<b>4.1.18</b>	ROC curve for Gelatinase-A (MMP-2) in oral cancer patients	<b>112</b>
<b>4.1.19</b>	Comparison of gelatinase-A (MMP-2) in oral SCC with lymphatic response and larger tumor size	<b>113</b>
<b>4.1.20</b>	Representative gelatin zymogram and standard curves for Gelatinase-B [MMP-9]: (A; Zymogram, B; latent, C; active) standards	<b>115</b>
<b>4.1.21</b>	Representative pattern for gelatinase-B (MMP-9) in oral SCC tissues	<b>115</b>
<b>4.1.22</b>	Comparison of Latent, active, total and activation ratio of Gelatinase-B (MMP-9) in oral SCC tissues	<b>117</b>
<b>4.1.23</b>	ROC curve for Gelatinase-B (MMP-9) in oral cancer patients	<b>118</b>
<b>4.1.24</b>	Comparison of percentage activity of gelatinase-A (MMP-2) and Gelatinase-B (MMP-9) between malignant and adjacent normal oral SCC tissues	<b>123</b>
	<b>Results 4.2</b>	
<b>4.1.24</b>	Standard curve for serum p53 antibodies	<b>126</b>
<b>4.2.25</b>	Comparison of mean values of serum auto p53 antibodies in controls and oral cancer patients	<b>127</b>
<b>4.2.26</b>	ROC curve for serum p53 autoantibodies in controls vs oral cancer patients	<b>127</b>
<b>4.2.27</b>	Comparison of serum p53 autoantibodies levels between pretreated oral cancer patients and their follow-up	<b>132</b>
<b>4.2.28</b>	Representative case for Complete-responders (CR)	<b>133</b>
<b>4.2.29</b>	Representative case for Non-responders (NR)	<b>133</b>
<b>4.2.30</b>	Standard curve for serum IL-8	<b>134</b>
<b>4.2.31</b>	Comparison of mean values of serum IL-8 in controls and oral cancer patients	<b>135</b>
<b>4.2.32</b>	ROC curve for serum IL-8 in controls vs oral cancer patients	<b>135</b>
<b>4.2.33</b>	Representative case for complete responder (CR)	<b>139</b>
<b>4.2.34</b>	Representative case for non-responder (NR)	<b>140</b>
<b>4.2.35</b>	Comparison of mean values of serum glycoprotein constituents in controls and oral cancer patients	<b>141</b>

<b>4.2.36</b>	ROC curve for serum glycoprotein constituents in controls vs oral cancer patients	<b>142</b>
<b>4.2.37</b>	Comparison of Mean values of Serum hexoses in oral cancer patients with tumor size and nuclear grade	<b>144</b>
<b>4.2.38</b>	Representative case for complete responder (CR)	<b>146</b>
<b>4.2.39</b>	Representative case for Non-responder (NR)	<b>147</b>
<b>4.2.40</b>	Standard curve for (A) Plasma Gelatinase-A (MMP-2) and its (B) tissue inhibitor TIMP-2	<b>149</b>
<b>4.2.41</b>	ROC curve for plasma gelatinase --A and its tissue inhibitor in controls vs oral cancer patients	<b>150</b>
<b>4.2.42</b>	Representative case for complete responder (CR)	<b>154</b>
<b>4.2.43</b>	Representative case for Non-responder (NR)	<b>154</b>
<b>4.2.44</b>	Standard curve for (A) Gelatinase-B (MMP-9) standard and (B) Standard curve for TIMP-1 standard	<b>155</b>
<b>4.2.45</b>	ROC curve for plasma gelatinase-- B and its tissue inhibitor in controls vs oral cancer patients	<b>156</b>
<b>4.2.46</b>	Representative case for complete responder (CR)	<b>161</b>
<b>4.2.47</b>	Representative case for Non-responder (NR)	<b>162</b>
<b>4.2.48</b>	Comparison of plasma levels of gelatinase-A (MMP-2), gelatinase-B (MMP-9), tissue inhibitors TIMP-1 and TIMP-2	<b>163</b>
<b>4.2.49</b>	Comparison of antioxidant and detoxification enzymes as well as thiol levels between controls and cancer patients	<b>167</b>
<b>4.2.50</b>	ROC curve for serum antioxidant and detoxifying enzymes in controls vs oral cancer patients	<b>168</b>
<b>4.2.51</b>	Correlation of antioxidant and detoxifying enzymes with the stage of the disease	<b>169</b>
<b>4.2.52</b>	Mean erythrocyte GST, GR, SOD and catalase levels in PT CR and NR	<b>169</b>
<b>4.2.53</b>	Comparison of plasma GST, GR and thiol levels between PT, CR and NR	<b>170</b>
	<b>Epilogue</b>	
<b>6.1</b>	Summary of diagnostic and prognostic implications of biomarkers in oral cancer	<b>203</b>